8-K: Celularity Announces CFO Transition, Appoints Interim Successor and Retains Financial Advisory Firm

Celularity Inc. announced the termination of its Chief Financial Officer, David Beers, without cause, and the appointment of Joseph DosSantos as interim CFO, while also retaining CFO Squad for financial and reporting support.

Summary

• Celularity Inc. terminated the employment of its Chief Financial Officer, David Beers, effective June 10, 2025.
• The termination was stated to be "without cause" and not related to the company's financial or operating results, nor to any disagreements regarding financial or reporting practices.
• Mr. Beers is entitled to payments and benefits as per his employment agreement, subject to his execution of a general release.
• Joseph DosSantos, currently Senior Vice President Finance, has been appointed as interim CFO, effective June 10, 2025.
• Mr. DosSantos will not receive additional compensation for his interim CFO role and will continue his Senior Vice President Finance duties.
• Celularity has retained CFO Squad, a financial and business advisory firm, to provide outsourced accounting, consulting, and SEC/financial reporting support during the transition period.
• CFO Squad will also assist in identifying opportunities to improve and optimize the company's financial processes and systems, working under the direction of John R. Haines, Celularity's Senior Executive Vice President and Chief Administrative Officer.

Sentiment

Score: 7

Explanation: While a CFO transition can be unsettling, the company's clear communication that the departure was 'without cause' and unrelated to financial performance, coupled with the immediate appointment of an internal interim CFO and the engagement of a specialized advisory firm for support and process optimization, indicates a well-managed transition. This proactive approach mitigates potential negative sentiment and suggests stability.

Positives

• The termination of the CFO was explicitly stated as "without cause" and not related to the company's financial or operating results, nor to any disagreements concerning financial or reporting practices, which mitigates concerns about underlying financial health or integrity.
• The immediate appointment of an internal candidate, Joseph DosSantos, as interim CFO ensures continuity in financial leadership.
• The retention of CFO Squad, a specialized financial advisory firm, provides additional support for SEC and financial reporting, and aims to optimize financial processes and systems, indicating a proactive approach to managing the transition and improving operations.
• The interim CFO, Joseph DosSantos, will not receive additional compensation for the role, potentially indicating cost efficiency during the transition.

Negatives

• The departure of a Chief Financial Officer, even if "without cause," can introduce uncertainty regarding leadership stability and future financial direction.
• A transition period for a key executive role like CFO may temporarily divert management attention and resources.

Risks

• The document explicitly states the termination was not related to financial or operating results or disagreements regarding financial or reporting practices, thereby mitigating common risks associated with CFO departures. No other specific risks are mentioned.

Future Outlook

The company is actively conducting a search for a new Chief Financial Officer and has retained a financial advisory firm, CFO Squad, to provide support during this interim period, including identifying opportunities to improve and optimize the company's financial processes and systems.

Management Comments

• "Celularity Inc. (the Company) terminated the employment of David Beers, its Chief Financial Officer without cause pursuant to Section 6.2 of the Amended and Restated Employment Agreement dated as of April 1, 2022 between the Company and Mr. Beers, as amended (the Agreement)."
• "Mr. Beers termination was not related to the Companys financial or operating results or to any disagreements or concerns regarding the Companys financial or reporting practices."
• "On June 10, 2025, the Company appointed Joseph DosSantos, its current Senior Vice President Finance, as the Companys interim CFO while the Company conducts a search for a new CFO."
• "Mr. DosSantos will continue to serve as the Companys Senior Vice President Finance during his time as interim CFO and will not receive any additional compensation in connection with his role as interim CFO."
• "Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period."

Industry Context

This announcement is specific to Celularity Inc.'s internal management structure and does not directly reflect broader industry trends in regenerative or cellular medicine. Executive transitions are common across all industries, and the company's proactive steps to ensure continuity and process improvement are standard practices during such changes.

Comparison to Industry Standards

• NA (This document does not provide financial or operational results for comparison).

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The clear communication regarding the CFO's departure not being related to financial performance or reporting practices aims to reassure shareholders. The appointment of an interim CFO and retention of an advisory firm suggest efforts to maintain stability and improve operations, which could be viewed positively.
• Employees: The transition may create some uncertainty, but the continuity plan with an internal interim appointment might help stabilize the finance department.
• Customers/Suppliers: Unlikely to have a direct impact from this specific announcement.
• Creditors: The statement that the departure is unrelated to financial results or practices may reassure creditors about the company's financial health.

Next Steps

• Celularity Inc. will conduct a search for a new Chief Financial Officer.
• CFO Squad will provide ongoing outsourced accounting, consulting, and SEC/financial reporting support.
• CFO Squad will work to identify opportunities to improve and optimize the company's financial processes and systems.

Key Dates

Keywords

Celularity, CELU, CFO, Chief Financial Officer, David Beers, Joseph DosSantos, CFO Squad, financial reporting, corporate governance, executive transition, regenerative medicine, cellular medicine, SEC filing, 8-K